Differential levels of soluble inflammatory markers by human immunodeficiency virus controller status and demographics

Open Forum Infectious Diseases

Volumn 2, Issue 1, 2015, Pages

  Li, Jonathan Z ^a   Arnold, Kelly B ^b   Lo, Janet ^c   Dugast, Anne Sophie ^b   Plants, Jill ^d   Ribaudo, Heather J ^e   Cesa, Kevin ^c   Heisey, Andrea ^a   Kuritzkes, Daniel R ^a   Lauffenburger, Douglas A ^b   Alter, Galit ^b   Landay, Alan ^d   Grinspoon, Steven ^c   Pereyra, Florencia ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antiretroviral therapy; Gender; HIV elite controllers; Inflammation; Low level viremia

Indexed keywords

CD14 ANTIGEN; CD163 ANTIGEN; CD40 LIGAND; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; SEX DIFFERENCE; VIREMIA; VIRUS LOAD;

EID: 84978328165     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofu117     Document Type: Article

References (49)

1. Nakagawa F, Lodwick RK, Smith CJ, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 2012; 26: 335-43.
2. Hogg R, Lima V, Sterne J, et al. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008; 372:293-9.
3. Masia M, Padilla S, Alvarez D, et al. Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients: role of antiretroviral therapy. AIDS 2013; 27:181-9.
4. Neuhaus J, Angus B, Kowalska JD, et al. Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV. AIDS 2010; 24:697-706.
5. Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 0:1-9.
6. Crowell TA, Gebo KA, Blankson JN, et al. HIV elite controllers are hospitalized more often than persons with medically controlled HIV. In: Conference on Retroviruses and Opportunistic Infections; March 3-6, 2014 (Abstract 556); Boston, MA.
7. Subramanian S, Tawakol A, Burdo TH, et al. Arterial inflammation in patients with HIV. JAMA 2012; 308:379-86.
8. Burdo TH, Lo J, Abbara S, et al. Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients. J Infect Dis 2011; 204:1227-36.
9. Kelesidis T, Kendall MA, Yang OO, et al. Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis 2012; 206:1558-67.
10. Tenorio A, Zheng E, Bosch RJ, et al. Soluble markers of inflammation and coagulation, but not T cell activation, predict non-AIDS-defining events during suppressive ART. In: 20th Conference on Retroviruses and Opportunistic Infections; March 3-Mar 6, 2012 (Abstract 790); Atlanta, GA.
11. Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006; 107:4781-9.
12. Hunt PW, Brenchley J, Sinclair E, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008; 197:126-33.
13. Hsue PY, Hunt PW, Schnell A, et al. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009; 23:1059-67.
14. Krishnan S, Wilson EM, Sheikh V, et al. Evidence for innate immune system activation in HIV type 1-infected elite controllers. J Infect Dis 2014; 209:931-9.
15. Pereyra F, Lo J, Triant VA, et al. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. AIDS 2012; 26:2409-12.
16. Pereyra F, Jia X, McLaren PJ, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010; 330:1551-7.
17. Pereyra F, Palmer S, Miura T, et al. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J Infect Dis 2009; 200:984-90.
18. Lau KS, Juchheim AM, Cavaliere KR, et al. In vivo systems analysis identifies spatial and temporal aspects of the modulation of TNF-alphainduced apoptosis and proliferation by MAPKs. Sci Signal 2011; 4:ra16.
19. Okulicz JF, Marconi VC, Landrum ML, et al. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis 2009; 200:1714-23.
20. Fabriek BO, Dijkstra CD, van den Berg TK. The macrophage scavenger receptor CD163. Immunobiology 2005; 210:153-60.
21. Hiki N, Berger D, Prigl C, et al. Endotoxin binding and elimination by monocytes: secretion of soluble CD14 represents an inducible mechanism counteracting reduced expression of membrane CD14 in patients with sepsis and in a patient with paroxysmal nocturnal hemoglobinuria. Infect Immun 1998; 66:1135-41.
22. Morange PE, Tiret L, Saut N, et al. TLR4/Asp299Gly, CD14/C-260 T, plasma levels of the soluble receptor CD14 and the risk of coronary heart disease: The PRIME Study. Eur J Hum Genet 2004; 12:1041-9.
23. Spivak AM, Salgado M, Rabi SA, et al. Circulating monocytes are not a major reservoir ofHIV-1 in elite suppressors. J Virol 2011; 85:10399-403.
24. Ferre AL, Hunt PW, Critchfield JW, et al. Mucosal immune responses to HIV-1 in elite controllers: a potential correlate of immune control. Blood 2009; 113:3978-89.
25. Vingert B, Benati D, Lambotte O, et al. HIV controllers maintain a population of highly efficient Th1 effector cells in contrast to patients treated in the long term. J Virol 2012; 86:10661-74.
26. Wang J, Harada A, Matsushita S, et al. IL-4 and a glucocorticoid upregulate CXCR4 expression on human CD4+ T lymphocytes and enhance HIV-1 replication. J Leukoc Biol 1998; 64:642-9.
27. Mikovits JA, Meyers AM, Ortaldo JR, et al. IL-4 and IL-13 have overlapping but distinct effects on HIV production in monocytes. J Leukoc Biol 1994; 56:340-6.
28. Naif HM, Li S, Ho-Shon M, et al. The state of maturation of monocytes into macrophages determines the effects of IL-4 and IL-13 on HIV replication. J Immunol 1997; 158:501-11.
29. Gauthier S, Tremblay MJ. Interleukin-4 inhibits an early phase in the HIV-1 life cycle in the human colorectal cell line HT-29. Clin Immunol 2010; 135:146-55.
30. Nakayama EE, Meyer L, Iwamoto A, et al. Protective effect of interleukin-4-589 T polymorphism on human immunodeficiency virus type 1 disease progression: relationship with virus load. J Infect Dis 2002; 185:1183-6.
31. Noel N, Boufassa F, Lecuroux C, et al. Elevated IP10 levels are associated with immune activation and low CD4(+) T-cell counts in HIV controller patients. AIDS 2014; 28:467-76.
32. Keating SM, Golub ET, Nowicki M, et al. The effect of HIV infection and HAART on inflammatory biomarkers in a population-based cohort of women. AIDS 2011; 25:1823-32.
33. Cozzi-Lepri A, French MA, Baxter J, et al. Resumption of HIV replication is associated with monocyte/macrophage derived cytokine and chemokine changes: results from a large international clinical trial. AIDS 2011; 25:1207-17.
34. Leeansyah E, Malone DF, Anthony DD, et al. Soluble biomarkers of HIV transmission, disease progression and comorbidities. Curr Opin HIV AIDS 2013; 8:117-24.
35. Jenabian MA, Patel M, Kema I, et al. Soluble CD40-ligand (sCD40L, sCD154) plays an immunosuppressive role via regulatory T-cell expansion in HIV infection. Clin Exp Immunol 2014; 178:102-11.
36. Stylianou E, Aukrust P, Bendtzen K, et al. Interferons and interferon (IFN)-inducible protein 10 during highly active anti-retroviral therapy (HAART)-possible immunosuppressive role of IFN-alpha in HIV infection. Clin Exp Immunol 2000; 119:479-85.
37. Watanabe D, Uehira T, Yonemoto H, et al. Sustained high levels of serum interferon-gamma during HIV-1 infection: a specific trend different from other cytokines. Viral Immunol 2010; 23:619-25.
38. Hatano H, Yukl SA, Ferre AL, et al. Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog 2013; 9: e1003691.
39. Chang JJ, Woods M, Lindsay RJ, et al. Higher expression of several interferon-stimulated genes in HIV-1-infected females after adjusting for the level of viral replication. J Infect Dis 2013; 208:830-8.
40. Meier A, Chang JJ, Chan ES, et al. Sex differences in the Toll-like receptor-mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med 2009; 15:955-9.
41. Borges AH, O'Connor JL, Phillips AN, et al. Factors associated with Ddimer levels in HIV-infected individuals. PLoS One 2014; 9:e90978.
42. Triant VA, Lee H, Hadigan C, et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 2506-12.
43. Fitch KV, Srinivasa S, Abbara S, et al. Atherosclerotic plaque and immune activation in HIV-infected women. J Infect Dis 2015. (In Press).
44. Groves KC, Bibby DF, Clark DA, et al. Disease progression in HIV-1-infected viremic controllers. J Acquir Immune Defic Syndr 2012; 61:407-16.
45. Boufassa F, Saez-Cirion A, Lechenadec J, et al. CD4 dynamics over a 15 year-period among HIV controllers enrolled in the ANRS French observatory. PLoS One 2011; 6:e18726.
46. Chun TW, Shawn Justement J, Murray D, et al. Effect of antiretroviral therapy on HIV reservoirs in elite controllers. J Infect Dis 2013; 208: 1443-7.
47. Boufassa F, Lechenadec J, Meyer L, et al. Blunted response to combination antiretroviral therapy in HIV elite controllers: an international HIV controller collaboration. PLoS One 2014; 9:e85516.
48. Asmuth DM, Ma ZM, Mann S, et al. Gastrointestinal-associated lymphoid tissue immune reconstitution in a randomized clinical trial of raltegravir versus non-nucleoside reverse transcriptase inhibitor-based regimens. AIDS 2012; 26:1625-34.
49. Mellors JW, Margolick JB, Phair JP, et al. Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 cell count slope for progression to AIDS and death in untreated HIV-1 infection. JAMA 2007; 297: 2349-50.